CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

NCT04785833 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

T-ALL

Interventions

DRUG: T cell injection targeting CD7 chimeric antigen receptor

Sponsor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Collaborators

[object Object]